Heikki Valleala

1.1k total citations
27 papers, 889 citations indexed

About

Heikki Valleala is a scholar working on Rheumatology, Oncology and Molecular Biology. According to data from OpenAlex, Heikki Valleala has authored 27 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Rheumatology, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Heikki Valleala's work include Rheumatoid Arthritis Research and Therapies (13 papers), Bone health and treatments (6 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Heikki Valleala is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (13 papers), Bone health and treatments (6 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Heikki Valleala collaborates with scholars based in Finland, Netherlands and India. Heikki Valleala's co-authors include Yrjö T. Konttinen, Seppo Santavirta, Timo Sorsa, Carlos López-Otı́n, Mari Ainola, Jin Ma, Jami Mandelin, Hideo Ida, Michiaki Takagi and Raimund W. Kinne and has published in prestigious journals such as Frontiers in Immunology, Annals of the Rheumatic Diseases and Life Sciences.

In The Last Decade

Heikki Valleala

27 papers receiving 863 citations

Peers

Countries citing papers authored by Heikki Valleala

Since Specialization

Citations

This map shows the geographic impact of Heikki Valleala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heikki Valleala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heikki Valleala more than expected).

Fields of papers citing papers by Heikki Valleala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heikki Valleala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heikki Valleala. The network helps show where Heikki Valleala may publish in the future.

Co-authorship network of co-authors of Heikki Valleala

This figure shows the co-authorship network connecting the top 25 collaborators of Heikki Valleala. A scholar is included among the top collaborators of Heikki Valleala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heikki Valleala. Heikki Valleala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combined Expression of IFN-γ, IL-17, and IL-4 mRNA by Recall PBMCs Moderately Discriminates Active Tuberculosis from Latent Mycobacterium tuberculosis Infection in Patients with Miscellaneous Inflammatory Underlying Conditions 2016 ·Frontiers in Immunology ·(unknown), Anu Kantele, Aija Knuuttila, (unknown), Riitta Karttunen, Heikki Valleala, Tamara Tuuminen	7
2	A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs. 2016 ·PubMed ·Kalle Aaltonen, (unknown), Tuulikki Sokka, Kari Puolakka, Heikki Valleala	10
3	Impact of physicians’ adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial 2015 ·Scandinavian Journal of Rheumatology ·(unknown), Kari Puolakka, Hannu Kautiainen, Harri Blåfield, (unknown), Kirsti Ilva, Oili Kaipiainen‐Seppänen, Anna Karjalainen, Markku Korpela, Heikki Valleala, Marjatta Leirisalo‐Repo, Vappu Rantalaiho, (unknown)	18
4	Long-Term Real-Life Experience With Rituximab in Adult Finnish Patients With Rheumatoid Arthritis Refractory or With Contraindication to Anti–Tumor Necrosis Factor Drugs 2015 ·JCR Journal of Clinical Rheumatology ·Heikki Valleala, Markku Korpela, (unknown), Kai Immonen, (unknown), (unknown), (unknown), Timo Möttönen, Pekka Hannonen	10
5	Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy 2015 ·The Journal of Rheumatology ·Kalle Aaltonen, (unknown), Liisa Virkki, Tuulikki Sokka, Pasi Aronen, Heikki Relas, Heikki Valleala, Vappu Rantalaiho, Laura Pirilä, Kari Puolakka, (unknown), Marja Blom, Yrjö T. Konttinen, Dan Nordström	65
6	Epstein-Barr virus in peripheral blood is associated with response to rituximab therapy in rheumatoid arthritis patients 2015 ·Clinical Rheumatology ·Heikki Valleala, Markku Kauppi, Vesa‐Petteri Kouri, Markku Korpela	4
7	A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland 2014 ·Scandinavian Journal of Rheumatology ·(unknown), Tuulikki Sokka, Timo Möttönen, Markku Korpela, (unknown), (unknown), (unknown), Toini Uutela, Heikki Valleala, (unknown)	4
8	Cytotoxic response persists in subjects treated for tuberculosis decades ago 2013 ·BMC Infectious Diseases ·(unknown), (unknown), Anu Kantele, Heikki Valleala, (unknown), Riitta Tuompo, Benita Westerlund‐Wikström, Tamara Tuuminen	1
9	Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial 2012 ·Scandinavian Journal of Rheumatology ·Markku Hakala, Heikki Kröger, Heikki Valleala, (unknown), Marjo Lehtonen-Veromaa, Jorma Heikkinen, (unknown), Pekka Hannonen, Leena Paimela, (unknown)	40
10	Biological Therapy for Psoriatic Arthritis in Clinical Practice: Outcomes Up to 2 Years 2010 ·The Journal of Rheumatology ·Liisa Virkki, (unknown), (unknown), Heikki Valleala, (unknown), Markku Kauppi, (unknown), Laura Pirilä, (unknown), (unknown), (unknown), (unknown), (unknown), Yrjö T. Konttinen, Dan Nordström	15
11	Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay 2010 ·Clinical Biochemistry ·Marja-Kaisa Koivula, Jill Richardson, Aila Leino, Heikki Valleala, (unknown), (unknown), Yrjö T. Konttinen, (unknown), Juha Risteli	24
12	A case of Poncet disease diagnosed with interferon-γ-release assays 2009 ·Nature Reviews Rheumatology ·Heikki Valleala, Tamara Tuuminen, Heikki Repo, Kari K. Eklund, Marjatta Leirisalo‐Repo	9
13	Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients 2009 ·Scandinavian Journal of Rheumatology ·Heikki Valleala, Markku Korpela, Timo Möttönen, (unknown), Markku Kauppi, Pekka Hannonen, Marjatta Leirisalo‐Repo	12
14	Erosive arthritis in a patient with pycnodysostosis: An experiment of nature 2008 ·PubMed ·Mari Ainola, Heikki Valleala, (unknown), Juha Risteli, Roeland Hanemaaijer, Yrjö T. Konttinen	11
15	Regression of heterotopic ossification after starting warfarin—an effect mediated by inhibition of γ-carboxylation of osteocalcin?—a case report 2007 ·Acta Orthopaedica ·Heikki Valleala, Tom Böhling, Yrjö T. Konttinen	4
16	Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates 2003 ·Life Sciences ·Heikki Valleala, Roeland Hanemaaijer, Johanna Mandelin, Antero Salminen, Olli Teronen, Jukka Mönkkönen, Yrjö T. Konttinen	40
17	Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis - a double blind placebo controlled study 2001 ·Inflammation Research ·Heikki Valleala, Kalevi Laitinen, Liisa Pylkkänen, Yrjö T. Konttinen, Claes Friman	9
18	Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis 1999 ·Annals of the Rheumatic Diseases ·Yrjö T. Konttinen, Mari Ainola, Heikki Valleala, Jin Ma, Hideo Ida, Jami Mandelin, Raimund W. Kinne, Seppo Santavirta, Timo Sorsa, Carlos López-Otı́n, Michiaki Takagi	342
19	Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate 1999 ·Matrix Biology ·Yrjö T. Konttinen, Tuula Salo, Roeland Hanemaaijer, Heikki Valleala, Timo Sorsa, Meeri Sutinen, Arnoldas Čeponis, (unknown), Seppo Santavirta, Olli Teronen, Carlos López-Otı́n	68
20	Inhibition of Matrix Metalloproteinase-1 by Dichloromethylene Bisphosphonate (Clodronate) 1997 ·Calcified Tissue International ·Olli Teronen, Y T Konttinen, Christer Lindqvist, Tuula Salo, Tuula Ingman, Anneli Lauhio, Y. Ding, Seppo Santavirta, Heikki Valleala, Timo Sorsa	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact